Key Drivers To Overcome Obstacles In mAbs Formulation And Fill-Finish

By Jerry Keybl, Senior VP of Biopharma Products And Strategy, Avantor

Designing an effective, stable and safe high-concentration mAb formulation presents critical challenges for biomanufacturers. Despite selecting the right, compendial excipients for a balanced formulation, you may encounter obstacles in fluid handling, regulatory compliance and the supply chain that must be addressed to meet market deadlines. Discover the key strategies to overcome, aided by comprehensive support from suppliers, to streamline the formulation and fill-finish process and deliver effective mAb therapies on time.